The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

This site is intended only for healthcare professionals of the United States, its territories, and Puerto Rico. Non-US residents click here.

5-Year Data See the results of the longest reported controlled clinical study of male pattern hair loss. View study results.

Hair Weight Results In the longest reported controlled clinical study of male pattern hair loss patients ever conducted ... PROPECIA® (finasteride) grew thicker and/or faster-growing natural hair In a 192-week study, a 46% difference (P<0.001) was observed in the mean percent change from baseline in hair weight between men treated with PROPECIA and men treated with placebo at Week 192.2 Please see Study Designs. Important Information About PROPECIA   PROPECIA is the first oral therapy indicated for the treatment of male pattern hair loss in MEN ONLY. Safety and efficacy were demonstrated in men, aged 18 to 41, with mild to moderate hair loss of the vertex and anterior mid-scalp area. Efficacy in bitemporal recession has not been established.   PROPECIA is not indicated in women or children. Clinical Hair Count Results Prescribing PROPECIA Highlights   PROPECIA is contraindicated in patients with hypersensitivity to any component of this medication.   Women should not handle crushed or broken PROPECIA tablets when they are pregnant or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus. PROPECIA tablets are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets have not been broken or crushed.

	PROPECIA is a registered trademark of Merck & Co., Inc. 20753248(2)-12/07–PRP